Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17285917 | 0.90 | KMT2A (0.49) | POLBHTTALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL13601455 | 0.87 | POLB (0.51) | POLBHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL8714816 | 0.86 | SMN1; SMN2 (0.47) | POLBALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL29700358 | 0.85 | LMNA (0.49) | POLBHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL8957048 | 0.85 | LMNA (0.49) | POLBHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL674463 | 0.85 | LMNA (0.49) | POLBHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL8714085 | 0.85 | SMN1; SMN2 (0.50) | POLBHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13601405 | 0.84 | POLB (0.49) | POLBHTTALDH1A1KMT2ALMNA | |
| SCHEMBL12881362 | 0.83 | GNAI3 (0.46) | POLBALDH1A1SMN1; SMN2KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL8713116 | 0.83 | SMN1; SMN2 (0.49) | POLBHTTALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962843-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962844-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150031659-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| US-20150031665-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| US-8940897-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8933232-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933233-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140315876-A1 | BETA-LACTAMASE INHIBITORS | CUBIST PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20130303504-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130296293-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-20130296291-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-20130296290-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-20130296292-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-7625886-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7625886-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-20090170749-A1 | Novel Compounds Which Interact With PEA-15 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170749-A1 | Novel Compounds Which Interact With PEA-15 | PEBP1, EPS15, PSTPIP2 | POLB 4785/4885HTT 4634/4885ALDH1A1 4723/4885 |
| US-20130296293-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | POLB 793/4885HTT 4826/4885ALDH1A1 167/4885 |
| US-20150031665-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | POLB 793/4885HTT 4826/4885ALDH1A1 167/4885 |
| US-20150031659-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, BBOX1 | POLB 871/4885HTT 4841/4885ALDH1A1 158/4885 |
| US-20130296290-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | POLB 793/4885HTT 4826/4885ALDH1A1 167/4885 |
| US-20130303504-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | POLB 793/4885HTT 4826/4885ALDH1A1 167/4885 |
| US-20130296291-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | POLB 793/4885HTT 4826/4885ALDH1A1 167/4885 |
| US-20140315876-A1 | BETA-LACTAMASE INHIBITORS | LCT, BCHE, GANAB | POLB 452/4885HTT 4702/4885ALDH1A1 842/4885 |
| US-20130296292-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | POLB 793/4885HTT 4826/4885ALDH1A1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.